Transcriptionology of recurrent meningiomas

Meningioma is a common primary tumor in the intracranial and vertebral tubes, 80% is benign, the prognosis of the full surgical excision is good, but 20% of meningiomas recur, need re-surgery or radiation therapyAt present, the main indicators for predicting the recurrence of meningioma are WHO classification and excision rangeAngela NViaene, of the Perelman School of Medicine at the University of Pennsylvania, usa, and others who use RNA sequencing to complement and improve the comenma tissue credit type to analyze the characteristics of tumor progression were published in Acta Neuropathologica Communications in April 2019the study method
the meningioma specimen, from the University of Pennsylvania Hospital, was diagnosed by a senior pathologist to exclude incomplete atypical and veinor or transparent cell meningioma for homogenization comparisonCollect clinical and demographic information about patients, including past history of radiation therapyA total of 25 meningioma specimens were included in the study, including 19 primary tumors (9 in WHO I, 7 in WHO II and 3 in WHO III) and 6 progressive tumorsParallel bioinformatics analysis of genetic sequencing of specimensIn addition, 3 types of tissue chips (TMA) were constructed from 71 cases of meningioma, including 15 cases of tumor recurrence or progression (13 from WHO Level I to WHO LEVEL II, 2 from WHO LEVEL II to WHO III) and 42 cases of non-progressive tumors (18 WHO I, 17 WHO II and 7 cases of III;of the six WHO Class I tumors, 4 were non-progressive (grade I never progressed, I.NP), and cluster ingressss showed significant independence from other tumorsProgressive WHO I(Grade IProgressiveed, I.P)tumors and their corresponding recurrent WHO CLASS II tumor cluster analysis suggest that most of the recurrent tumors are similar to primary tumorsUnsupervised clustering analysis found that only WHO Level I tumors (i.eI.Pand I.NP) had significant characteristics WHO Level II tumor clustering characteristics are difficult to unify the results 38 tumor specimens (of which 20 in WHO I, 12 in WHO II and 6 in WHO III) were used in 38 different patients for quantitative reverse transcription (qRT)-PCR validation, and 28 (74%) were women At the time of the operation, the age was 34-88 years old and the median was 55 years old 6 (16%) tumors invade brain tissue (3 WHO-CLASS II meningenomas and 3 WHO-CLASS III meningengocents) In different stages of meningioma, RNA-seq analysis found that GREM2, which regulates the BMP signaling pathway, and snoRNA, snoRA46, and snoRA48 were significantly reduced in progressive meningiomas; WHO Class I non-progressive meningioma had significant CD45-positive cells compared to WHO II and III meningiomas, i.e peripheral macrophages were immersed, and the number of inflammatory cells increased significantly The results are consistent with Genomic Enrichment Analysis (Gene Set Enrichment Analysis, GSEA) and indicate an increase in immune activity in low-level meningioma microenvironments conclusions the authors note that the results of the study were a distinction between transcriptional characteristics of progression and non-progressive WHO-grade meningioma, as well as new targets for diagnosis and treatment of meningioma, such as GREM2 and snoRNA genes In addition, WHO Class I meningiomas are significantly higher than malignant tumors in immune cell leaching The progression characteristics of WHO I.-grade meningioma provide direction for future diagnosis and treatment.